Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00390234 · FLOW

Participant flow

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma · Source last updated 2015-12-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. ziv-aflibercept: Given IV laboratory biomarker analysis: Correlative studies pharmacological study: Correlative studies
    id
    FG000
    title
    Treatment (Ziv-aflibercept)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. ziv-aflibercept: Given IV laboratory biomarker analysis: Correlative studies pharmacological study: Correlative studies
    id
    FG000
    title
    Treatment (Ziv-aflibercept)
periods
  1. milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        63
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice